Literature DB >> 12719599

RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells.

Allison H S Hall1, Kenneth A Alexander.   

Abstract

The human papillomavirus oncoproteins E6 and E7 promote cell proliferation and contribute to carcinogenesis by interfering with the activities of cellular tumor suppressors. We used a small interfering RNA molecule targeting the E7 region of the bicistronic E6 and E7 mRNA to induce RNA interference, thereby reducing expression of E6 and E7 in HeLa cells. RNA interference of E6 and E7 also inhibited cellular DNA synthesis and induced morphological and biochemical changes characteristic of cellular senescence. These results demonstrate that reducing E6 and E7 expression is sufficient to cause HeLa cells to become senescent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719599      PMCID: PMC154052          DOI: 10.1128/jvi.77.10.6066-6069.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

Review 1.  RNA interference--2001.

Authors:  P A Sharp
Journal:  Genes Dev       Date:  2001-03-01       Impact factor: 11.361

Review 2.  RNA interference: antiviral defense and genetic tool.

Authors:  Bryan R Cullen
Journal:  Nat Immunol       Date:  2002-07       Impact factor: 25.606

Review 3.  The human papillomavirus E6 protein and its contribution to malignant progression.

Authors:  F Mantovani; L Banks
Journal:  Oncogene       Date:  2001-11-26       Impact factor: 9.867

Review 4.  Biological activities and molecular targets of the human papillomavirus E7 oncoprotein.

Authors:  K Münger; J R Basile; S Duensing; A Eichten; S L Gonzalez; M Grace; V L Zacny
Journal:  Oncogene       Date:  2001-11-26       Impact factor: 9.867

5.  Transactivation-competent bovine papillomavirus E2 protein is specifically required for efficient repression of human papillomavirus oncogene expression and for acute growth inhibition of cervical carcinoma cell lines.

Authors:  E C Goodwin; L K Naeger; D E Breiding; E J Androphy; D DiMaio
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway.

Authors:  K Webster; J Parish; M Pandya; P L Stern; A R Clarke; K Gaston
Journal:  J Biol Chem       Date:  2000-01-07       Impact factor: 5.157

7.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.

Authors:  S M Elbashir; J Harborth; W Lendeckel; A Yalcin; K Weber; T Tuschl
Journal:  Nature       Date:  2001-05-24       Impact factor: 49.962

Review 8.  Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis.

Authors:  H zur Hausen
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

9.  Rapid induction of senescence in human cervical carcinoma cells.

Authors:  E C Goodwin; E Yang; C J Lee; H W Lee; D DiMaio; E S Hwang
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

10.  Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference.

Authors:  Ming Jiang; Jo Milner
Journal:  Oncogene       Date:  2002-09-05       Impact factor: 9.867

View more
  61 in total

Review 1.  Cellular senescence in cancer treatment: friend or foe?

Authors:  Pascal Kahlem; Bernd Dörken; Clemens A Schmitt
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

2.  Growth inhibition of HeLa cells is a conserved feature of high-risk human papillomavirus E8^E2C proteins and can also be achieved by an artificial repressor protein.

Authors:  Jasmin Fertey; José Hurst; Elke Straub; Astrid Schenker; Thomas Iftner; Frank Stubenrauch
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

3.  Targeting the human papillomavirus E6 and E7 oncogenes through expression of the bovine papillomavirus type 1 E2 protein stimulates cellular motility.

Authors:  Monique A Morrison; Richard J Morreale; Shailaja Akunuru; Matthew Kofron; Yi Zheng; Susanne I Wells
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

4.  Deregulation of eIF4E: 4E-BP1 in differentiated human papillomavirus-containing cells leads to high levels of expression of the E7 oncoprotein.

Authors:  Kwang-Jin Oh; Anna Kalinina; No-Hee Park; Srilata Bagchi
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

Review 5.  Papillomavirus genome structure, expression, and post-transcriptional regulation.

Authors:  Zhi-Ming Zheng; Carl C Baker
Journal:  Front Biosci       Date:  2006-09-01

6.  The transcription factors TBX2 and TBX3 interact with human papillomavirus 16 (HPV16) L2 and repress the long control region of HPVs.

Authors:  Marc A Schneider; Konstanze D Scheffer; Timo Bund; Fatima Boukhallouk; Carsten Lambert; Cristina Cotarelo; Gert O Pflugfelder; Luise Florin; Gilles A Spoden
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

7.  Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions.

Authors:  Wei Feng; Xiuzhen Duan; Jinsong Liu; Jianguo Xiao; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02

8.  Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.

Authors:  Changyou Li; Daniel E Johnson
Journal:  Cell Cycle       Date:  2013-02-19       Impact factor: 4.534

9.  Interferon Kappa Inhibits Human Papillomavirus 31 Transcription by Inducing Sp100 Proteins.

Authors:  Christina Habiger; Günter Jäger; Michael Walter; Thomas Iftner; Frank Stubenrauch
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

Review 10.  Targeting human papillomavirus genome replication for antiviral drug discovery.

Authors:  Jacques Archambault; Thomas Melendy
Journal:  Antivir Ther       Date:  2013-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.